The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1(-/-) mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 1, 2009, Pages 287-296

  Endres, Christopher J ^a,c   Moss, Aaron M ^a   Govindarajan, Rajgopal ^a,d   Choi, Doo Sup ^b   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; RIBAVIRIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG URINE LEVEL; ERYTHROCYTE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; ERYTHROCYTES; FEMALE; MALE; MICE; MICE, KNOCKOUT; MOUTH MUCOSA; NUCLEOSIDE TRANSPORT PROTEINS; RIBAVIRIN; TISSUE DISTRIBUTION;

EID: 70349330683     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.153130     Document Type: Article

References (26)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, and Alter MJ (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705-714. (Pubitemid 46780630)
2. Austin RK, Trefts PE, Hintz M, Connor JD, and Kagnoff MF (1983) Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin. Antimicrob Agents Chemother 24:696-701. (Pubitemid 14203868)
3. Canonico PG, Kastello MD, Spears CT, Brown JR, Jackson EA, and Jenkins DE (1984) Effects of ribavirin on red blood cells. Toxicol Appl Pharmacol 74:155-162. (Pubitemid 14083681)
4. +-dependent and Na+-independent nucleoside transporters in Xenopus laevis oocytes. Biochem Pharmacol 53:1909-1918.
5. Connor E, Morrison S, Lane J, Oleske J, Sonke RL, and Connor J (1993) Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 37:532-539. (Pubitemid 23072599)
6. Endres CJ, Moss AM, Ke B, Govindarajan R, Choi DS, Messing RO, and Unadkat JD (2009) The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. J Pharmacol Exp Ther 329:387-398.
7. FDA (2007a) Copegus® (Ribavirin, USP) Tablets, in Hoffman-La Roche Inc., Nutley, NJ. NDA 21-511/S014.
8. FDA (2007b) Rebetol® (Ribavirin, USP) Capsules and Oral Solution, in Hoffman-La Roche Inc., Nutley, NJ. NDA 21-511/S014. Schering-Plough Corporation. Kenilworth, NJ. NDA 20-903/S-040.
9. Fried MW (2002) Side effects of therapy of hepatitis C and their management. Hepatology 36:S237-S244. (Pubitemid 35253486)
10. Govindarajan R, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M, Tse CM, Hayashi J, and Unadkat JD (2007) In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am J Physiol Regul Integr Comp Physiol 293:R1809-R1822. (Pubitemid 350085657)
11. Homma M, Matsuzaki Y, Inoue Y, Shibata M, Mitamura K, Tanaka N, and Kohda Y (2004) Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2:337-339. (Pubitemid 38447199)
12. Hu H, Endres CJ, Chang C, Umapathy NS, Lee EW, Fei YJ, Itagaki S, Swaan PW, Ganapathy V, and Unadkat JD (2006) Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3). Mol Pharmacol 69:1542-1553.
13. Inoue Y, Homma M, Matsuzaki Y, Shibata M, Matsumura T, Ito T, and Kohda Y (2006) Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res 34:23-27. (Pubitemid 43091872)
14. Jarvis SM, Thorn JA, and Glue P (1998) Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 123:1587-1592.
15. Lai Y, Bakken AH, and Unadkat JD (2002) Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin-Darby canine kidney cells. Localization and vectorial transport studies. J Biol Chem 277:37711-37717.
16. Laskin OL, Longstreth JA, Hart CC, Scavuzzo D, Kalman CM, Connor JD, and Roberts RB (1987) Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 41:546-555. (Pubitemid 17165697)
17. Lin CC, Yeh LT, Luu T, Lourenco D, and Lau JY (2003) Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. Antimicrob Agents Chemother 47:1395-1398. (Pubitemid 36368603)
18. Moss AM, Endres CJ, Govindarajan R, and Unadkat JD (2007) The role of the equilibrative nucleoside transporter 1 (Ent1) in the intestinal absorption of ribavirin in the wild-type and mENT1(-/-) mice. AAPS J 9:(S2).
19. Parker WB (2005) Metabolism and antiviral activity of ribavirin. Virus Res 107:165-171.
20. Paroni R, Del Puppo M, Borghi C, Sirtori CR, and Galli Kienle M (1989) Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. Int J Clin Pharmacol Ther Toxicol 27:302-307. (Pubitemid 19147153)
21. Patil SD, Ngo LY, Glue P, and Unadkat JD (1998) Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter. Pharmacol Res 15:950-952. (Pubitemid 28307840)
22. Patil SD and Unadkat JD (1997) Sodium-dependent nucleoside transport in the human intestinal brush-border membrane. Am J Physiol 272:G1314-G1320. (Pubitemid 127751009)
23. Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, and McNamara P (1999) Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother 43:2451-2456. (Pubitemid 29471226)
24. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, and Palasciano G (2006) Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 13:3351-3357. (Pubitemid 44669779)
25. Sherlock S (1995) Antiviral therapy for chronic hepatitis C viral infection. J Hepatol 23 (Suppl 2):3-7. (Pubitemid 26047360)
26. Yamamoto T, Kuniki K, Takekuma Y, Hirano T, Iseki K, and Sugawara M (2007) Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. Eur J Pharmacol 557:1-8. (Pubitemid 46135552)